SuperworthARK Genomic Revolution ETF
ARK ETF TrustSmall and mid blend
Run by ARK Investment Management, Cathie Wood's firm.
- Net assets
- $1.6B
- Stocks held
- 32
- As of
- Jul 31, 2026
- N-PORT filed with the SEC
- In its top 10
- 59%
- of net assets
- Active share
- 98%
- different from S&P Completion
Largest holdings
TXG9.4%TWST7.7%TEM6.6%CRSP6.3%PSNL5.5%ABSI5.1%GH4.7%ILMN4.7%LLY4.7%CDNA4.3%NTRA4.1%BEAM3.8%CMPS3.3%RXRX2.6%
| Company | Of net assets, over time | Share of S&P Completion |
|---|---|---|
| TXG10x Genomics | 0.05% | |
| TWSTTwist Bioscience | 0.08% | |
| TEMTempus AI | 0.07% | |
| CRSPCRISPR Therapeutics | 0.06% | |
| PSNLPersonalis | 0.01% | |
| ABSIAbsci | 0.02% | |
| GHGuardant Health | 0.23% | |
| ILMNIllumina | 0.31% | |
| LLYEli Lilly and | 0.00% | |
| CDNACareDx | 0.02% | |
| NTRANatera | 0.46% | |
| BEAMBeam Therapeutics | 0.04% | |
| CMPSCOMPASS Pathways | 0.00% | |
| RXRXRecursion Pharmaceuticals | 0.02% | |
| ADPTAdaptive Biotechnologies | 0.03% | |
| VCYTVeracyte | 0.06% | |
| NRIXNurix Therapeutics | 0.03% | |
| BFLYButterfly Network | 0.02% | |
| SDGRSchrodinger | 0.01% | |
| WGSGeneDx | 0.02% | |
| NTLAIntellia Therapeutics | 0.03% | |
| IONSIonis Pharmaceuticals | 0.15% | |
| ALMRAlamar Biosciences | 0.00% | |
| PRMEPrime Medicine | 0.00% | |
| GENBGenerate Biomedicines | 0.01% |
Its bets against S&P Completion
Each stock's weight of the fund's net assets less its weight in the S&P Completion, in points.
Holds much more than the index
Holds much less, or none
About these numbers
Holdings from the fund's N-PORT report to the SEC, public 60 days after the report date. Every weight is a percent of the fund's net assets, as the fund publishes it, and active weights are that less the index's weight. Only stocks are listed, so cash, bonds and derivatives are not, and a fund that borrows can hold stocks worth more than its net assets. Active share compares the fund's stocks alone with the index.